date:Jan 17, 2013
Revenues were 179 million, up 7% compared to Q1 2011/12, with organic revenue growth 5% (7% adjusted for lower sales prices to reflect lower raw material prices for carmine). EBIT was 48 million, up 16% compared to Q1 2011/12. EBIT margin was 26.7%, up from 24.5% in the corresponding previous year quarter.
The solid momentum in the Cultures Enzymes Division continued with 10% organic growth driven by our innovative product portfolio, said CEO Lars Frederiksen.
The Health Nutrition Division a